NEXGEL, Inc.

Equities

NXGL

US65344E1073

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-07-08 pm EDT 5-day change 1st Jan Change
2.04 USD -7.69% Intraday chart for NEXGEL, Inc. -4.67% -4.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NEXGEL, Inc. Provides Preliminary Revenue Guidance for the Second, Third and Fourth Quarter of 2024 CI
NEXGEL Secures Distribution Deal for SilverSeal Wound Dressing With Cintas MT
Nexgel, Inc. to Supply Silverseal to Cintas Corporation CI
Nexgel and Stada Partner to Launch Leading European Dao Enzyme Supplement, Histasolv, in North America CI
NEXGEL, Inc. acquired Silly George. CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022. CI
NEXGEL, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : NEXGEL, Inc., Q1 2024 Earnings Call, May 13, 2024
Earnings Flash (NXGL) NEXGEL Reports Q1 Revenue $1.3M, vs. Street Est of $1.2M MT
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022. CI
NEXGEL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : NEXGEL, Inc., Q4 2023 Earnings Call, Apr 01, 2024
Earnings Flash (NXGL) NEXGEL Posts Q4 Revenue $1.1M MT
NEXGEL, Inc. Provides Revenue Guidance for the First Quarter of 2023 CI
NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024 CI
Top Premarket Decliners MT
Nexgel Subsidiary, Cg Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024 CI
NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors CI
Nexgel Enters Deal With Stada Arzneimittel to Distribute OTC Products Across North America MT
NEXGEL, Inc. Announces Partnership with STADA Arzneimittel AG to Distribute and Commercialize Consumer Health OTC Products in North America CI
NEXGEL, Inc. acquired Kenkoderm from Olympus Trading Company, LLC for $1.1 million. CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022. CI
NEXGEL, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : NEXGEL, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Earnings Flash (NXGL) NEXGEL Reports Q3 Revenue $1.2M, vs. Street Est of $1.2M MT
Chart NEXGEL, Inc.
More charts
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. It also specializes in eye and eyelash consumer products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.04 USD
Average target price
6 USD
Spread / Average Target
+194.12%
Consensus
  1. Stock Market
  2. Equities
  3. NXGL Stock
  4. News NEXGEL, Inc.
  5. Nexgel Enters Deal With Stada Arzneimittel to Distribute OTC Products Across North America